JP2004501618A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004501618A5 JP2004501618A5 JP2002504289A JP2002504289A JP2004501618A5 JP 2004501618 A5 JP2004501618 A5 JP 2004501618A5 JP 2002504289 A JP2002504289 A JP 2002504289A JP 2002504289 A JP2002504289 A JP 2002504289A JP 2004501618 A5 JP2004501618 A5 JP 2004501618A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- polypeptide
- seq
- isolated polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 description 29
- 102000004196 processed proteins & peptides Human genes 0.000 description 29
- 108090000765 processed proteins & peptides Proteins 0.000 description 29
- 125000003275 alpha amino acid group Chemical group 0.000 description 21
- 241000193998 Streptococcus pneumoniae Species 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21268300P | 2000-06-20 | 2000-06-20 | |
| US60/212,683 | 2000-06-20 | ||
| PCT/CA2001/000908 WO2001098334A2 (en) | 2000-06-20 | 2001-06-19 | Streptococcus antigens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012117846A Division JP5889103B2 (ja) | 2000-06-20 | 2012-05-23 | ストレプトコッカス抗原 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004501618A JP2004501618A (ja) | 2004-01-22 |
| JP2004501618A5 true JP2004501618A5 (enExample) | 2008-08-07 |
| JP5051959B2 JP5051959B2 (ja) | 2012-10-17 |
Family
ID=22792041
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002504289A Expired - Fee Related JP5051959B2 (ja) | 2000-06-20 | 2001-06-19 | ストレプトコッカス抗原 |
| JP2012117846A Expired - Fee Related JP5889103B2 (ja) | 2000-06-20 | 2012-05-23 | ストレプトコッカス抗原 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012117846A Expired - Fee Related JP5889103B2 (ja) | 2000-06-20 | 2012-05-23 | ストレプトコッカス抗原 |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP2281891A3 (enExample) |
| JP (2) | JP5051959B2 (enExample) |
| KR (1) | KR100927767B1 (enExample) |
| CN (2) | CN101260149B (enExample) |
| AR (1) | AR033980A1 (enExample) |
| AU (2) | AU7038101A (enExample) |
| CA (1) | CA2413450C (enExample) |
| CZ (1) | CZ2003154A3 (enExample) |
| EA (1) | EA006232B1 (enExample) |
| HU (1) | HU228706B1 (enExample) |
| IL (2) | IL153558A0 (enExample) |
| MX (1) | MXPA03000103A (enExample) |
| NO (1) | NO331103B1 (enExample) |
| NZ (1) | NZ553554A (enExample) |
| PL (1) | PL214229B1 (enExample) |
| TR (1) | TR200704553T2 (enExample) |
| UY (1) | UY26783A1 (enExample) |
| WO (1) | WO2001098334A2 (enExample) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7128918B1 (en) | 1998-12-23 | 2006-10-31 | Id Biomedical Corporation | Streptococcus antigens |
| US7074415B2 (en) | 2000-06-20 | 2006-07-11 | Id Biomedical Corporation | Streptococcus antigens |
| US7262024B2 (en) | 2001-12-20 | 2007-08-28 | Id Biomedical Corporation | Streptococcus antigens |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| TW201350129A (zh) | 2005-12-22 | 2013-12-16 | Glaxosmithkline Biolog Sa | 包含莢膜醣結合物之肺炎鏈球菌免疫原組合物、包含其之疫苗及套組及其用途 |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| PL2097102T3 (pl) | 2006-09-07 | 2012-10-31 | Glaxosmithkline Biologicals Sa | Szczepionka skojarzona o zmniejszonej ilości antygenu wirusa polio |
| EA200901340A1 (ru) | 2007-05-02 | 2010-04-30 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина |
| US9610340B2 (en) | 2007-06-26 | 2017-04-04 | Glaxosmithkline Biologicals, S.A. | Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates |
| JP2010535015A (ja) * | 2007-07-23 | 2010-11-18 | サノフィ パストゥール リミテッド | 免疫原性のポリペプチドおよびモノクローナル抗体 |
| PL2271360T3 (pl) | 2008-04-16 | 2016-03-31 | Glaxosmithkline Biologicals Sa | Szczepionka |
| CN102223876A (zh) | 2008-09-26 | 2011-10-19 | 纳米生物公司 | 纳米乳剂治疗性组合物及其使用方法 |
| CA2757620C (en) | 2009-04-30 | 2016-04-26 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
| WO2010132833A1 (en) | 2009-05-14 | 2010-11-18 | The Regents Of The University Of Michigan | Streptococcus vaccine compositions and methods of using the same |
| WO2010141312A2 (en) | 2009-06-01 | 2010-12-09 | Wake Forest University Health Sciences | Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same |
| MX2012002639A (es) | 2009-09-03 | 2012-03-14 | Pfizer Vaccines Llc | Vacuna de pcsk9. |
| GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB201003920D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
| KR101272351B1 (ko) | 2010-04-23 | 2013-06-07 | 이화여자대학교 산학협력단 | 새로운 카나마이신 화합물, 카나마이신 생산 스트렙토마이세스 속 미생물 및 카나마이신의 생산 방법 |
| EP2680883B1 (en) | 2011-03-02 | 2018-09-05 | Pfizer Inc | Pcsk9 vaccine |
| AU2012257771C1 (en) | 2011-05-17 | 2015-12-03 | Glaxosmithkline Biologicals S.A. | Vaccine against Streptococcus pneumoniae |
| WO2015095868A1 (en) | 2013-12-20 | 2015-06-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| HUE064837T2 (hu) | 2014-01-21 | 2024-05-28 | Pfizer | Streptococcus pneumoniae kapszuláris poliszacharidok és azok konjugátumai |
| DK3096785T3 (da) | 2014-01-21 | 2020-09-21 | Pfizer | Immunogene sammensætninger omfattende konjugerede kapsel-saccharid-antigener og anvendelser deraf |
| RU2710393C2 (ru) | 2014-01-21 | 2019-12-26 | Пфайзер Инк. | Способ получения иммуногенного конъюгата капсульный полисахарид Streptococcus pneumoniae-белок-носитель |
| ES2701169T3 (es) | 2014-02-14 | 2019-02-21 | Pfizer | Conjugados glucoproteicos inmunogénicos |
| AU2016207820B2 (en) | 2015-01-15 | 2020-12-17 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| JP6994453B2 (ja) | 2015-07-21 | 2022-01-14 | ファイザー・インク | コンジュゲート化莢膜糖類抗原を含む免疫原性組成物、それを含むキットおよびこれらの使用 |
| GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
| JP6884145B2 (ja) | 2015-11-20 | 2021-06-09 | ファイザー・インク | 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物 |
| BR112019014833A2 (pt) | 2017-01-20 | 2020-04-14 | Pfizer | composições imunogênicas para uso em vacinas pneumococais |
| CN110225764A (zh) | 2017-01-31 | 2019-09-10 | 默沙东公司 | 制备多糖-蛋白缀合物的方法 |
| US20200222550A1 (en) | 2017-01-31 | 2020-07-16 | Merck Sharp & Dohme Corp. | Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f |
| US20200054740A1 (en) | 2017-02-24 | 2020-02-20 | Merck Sharp & Dohme Corp. | Pneumococcal conjugate vaccine formulations |
| RS65893B1 (sr) | 2017-09-07 | 2024-09-30 | Merck Sharp & Dohme Llc | Pneumokokni polisaharidi i njihova primena u imunogenim konjugatima polisaharid-proteinski nosač |
| EA202091382A1 (ru) | 2017-12-06 | 2021-01-15 | Мерк Шарп И Доум Корп. | Композиции, содержащие конъюгаты полисахарид streptococcus pneumoniae с белком, и способы их применения |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| CA3120922A1 (en) | 2018-12-12 | 2020-06-18 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
| SG11202106541WA (en) | 2018-12-19 | 2021-07-29 | Merck Sharp & Dohme | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| EP3952906A1 (en) | 2019-04-10 | 2022-02-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| PH12022550110A1 (en) | 2019-07-31 | 2022-12-12 | Sk Bioscience Co Ltd | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
| AU2020375214B2 (en) | 2019-11-01 | 2024-02-08 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| BR112022015796A2 (pt) | 2020-02-21 | 2022-10-11 | Pfizer | Purificação de sacarídeos |
| IL295632A (en) | 2020-02-23 | 2022-10-01 | Pfizer | Escherichia coli compositions and methods thereof |
| US20230383324A1 (en) | 2020-10-22 | 2023-11-30 | Pfizer Inc. | Methods for purifying bacterial polysaccharides |
| MX2023004912A (es) | 2020-10-27 | 2023-05-16 | Pfizer | Composiciones de escherichia coli y metodos de las mismas. |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| JP2022075575A (ja) | 2020-11-04 | 2022-05-18 | ファイザー・インク | 肺炎球菌ワクチンにおける使用のための免疫原性組成物 |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| TW202245835A (zh) | 2021-02-04 | 2022-12-01 | 美商默沙東有限責任公司 | 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物 |
| WO2022234405A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| EP4346893A2 (en) | 2021-05-28 | 2024-04-10 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| KR20230175284A (ko) | 2021-05-28 | 2023-12-29 | 화이자 인코포레이티드 | 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도 |
| US20250381259A1 (en) | 2022-01-13 | 2025-12-18 | Pfizer Inc. | Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof |
| WO2023161817A1 (en) | 2022-02-25 | 2023-08-31 | Pfizer Inc. | Methods for incorporating azido groups in bacterial capsular polysaccharides |
| EP4522208A1 (en) | 2022-05-11 | 2025-03-19 | Pfizer Inc. | Process for producing of vaccine formulations with preservatives |
| WO2024084397A1 (en) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| WO2024110827A1 (en) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Methods for preparing conjugated capsular saccharide antigens and uses thereof |
| CN120265317A (zh) | 2022-11-22 | 2025-07-04 | 辉瑞公司 | 包含经缀合的荚膜糖抗原的免疫原性组合物及其用途 |
| WO2024116096A1 (en) | 2022-12-01 | 2024-06-06 | Pfizer Inc. | Pneumococcal conjugate vaccine formulations |
| WO2024166008A1 (en) | 2023-02-10 | 2024-08-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN121038808A (zh) | 2023-03-30 | 2025-11-28 | 辉瑞公司 | 包含缀合的荚膜糖抗原的免疫原性组合物及其用途 |
| CN121057590A (zh) | 2023-04-14 | 2025-12-02 | 辉瑞公司 | 包含缀合荚膜糖抗原的免疫原性组合物及其用途 |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| TW202500153A (zh) | 2023-05-18 | 2025-01-01 | 美商默沙東有限責任公司 | 用於肺炎鏈球菌疫苗之化合物及佐劑調配物 |
| WO2024241172A2 (en) | 2023-05-19 | 2024-11-28 | Glaxosmithkline Biologicals Sa | Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection |
| TW202527906A (zh) | 2023-09-14 | 2025-07-16 | 美商輝瑞股份有限公司 | 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途 |
| WO2025106603A1 (en) | 2023-11-16 | 2025-05-22 | Merck Sharp & Dohme Llc | Peptide conjugate vaccine compositions and methods for the treatment of alzheimer's disease |
| WO2025133971A1 (en) | 2023-12-23 | 2025-06-26 | Pfizer Inc. | Improved methods for producing bacterial capsular saccharide glycoconjugates |
| WO2025186705A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2025191415A1 (en) | 2024-03-11 | 2025-09-18 | Pfizer Inc. | Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof |
| WO2025219904A1 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Improved methods for producing glycoconjugates by reductive amination in aprotic solvent |
| WO2025219908A2 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Media and fermentation methods for polysaccharide production in bacterial cell culture |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4425437A (en) | 1979-11-05 | 1984-01-10 | Genentech, Inc. | Microbial polypeptide expression vehicle |
| US4431739A (en) | 1979-11-05 | 1984-02-14 | Genentech, Inc. | Transformant bacterial culture capable of expressing heterologous protein |
| US4338397A (en) | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
| US5866135A (en) * | 1994-04-21 | 1999-02-02 | North American Vaccine, Inc. | Group A streptococcal polysaccharide immunogenic compositions and methods |
| KR19990007777A (ko) * | 1995-06-07 | 1999-01-25 | 듀크두플레시스 | 면역성 및 면역자극성 올리고당 조성물 및 이를 제조하고 이용하는 방법 |
| CA2271720A1 (en) * | 1996-10-31 | 1998-05-07 | Human Genome Sciences, Inc. | Streptococcus pneumoniae polynucleotides and sequences |
| KR20010024299A (ko) * | 1997-09-24 | 2001-03-26 | 리전츠 오브 더 유니버스티 오브 미네소타 | 스트렙토코쿠스 뉴모니애로부터의 사람 보체 ｃ3 분해단백질분해효소 |
| EP2053126A1 (en) * | 1998-07-27 | 2009-04-29 | Sanofi Pasteur Limited | Streptococcus pneumoniae proteins and nucleic acid molecules |
| HUP0103100A3 (en) * | 1998-08-19 | 2005-11-28 | Baxter Healthcare Sa | Immunogenic betha-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide |
| AU6060899A (en) * | 1998-09-24 | 2000-04-10 | American Cyanamid Company | Human complement c3-degrading polypeptide from (streptococcus pneumoniae) |
| DK1140157T3 (da) * | 1998-12-21 | 2009-06-08 | Medimmune Inc | Streptococcus pneumoniae-proteiner og immunogene fragmenter til vacciner |
| CN1191362C (zh) * | 1998-12-23 | 2005-03-02 | 夏尔生化公司 | 新颖的链球菌抗原 |
-
2001
- 2001-06-19 CN CN200710181645.XA patent/CN101260149B/zh not_active Expired - Fee Related
- 2001-06-19 EP EP10179497A patent/EP2281891A3/en not_active Withdrawn
- 2001-06-19 KR KR1020027017453A patent/KR100927767B1/ko not_active Expired - Fee Related
- 2001-06-19 HU HU0301656A patent/HU228706B1/hu not_active IP Right Cessation
- 2001-06-19 WO PCT/CA2001/000908 patent/WO2001098334A2/en not_active Ceased
- 2001-06-19 CN CN01814388A patent/CN1449446A/zh active Pending
- 2001-06-19 MX MXPA03000103A patent/MXPA03000103A/es active IP Right Grant
- 2001-06-19 NZ NZ553554A patent/NZ553554A/en not_active IP Right Cessation
- 2001-06-19 IL IL15355801A patent/IL153558A0/xx unknown
- 2001-06-19 CA CA2413450A patent/CA2413450C/en not_active Expired - Fee Related
- 2001-06-19 EP EP01949136A patent/EP1303612A2/en not_active Withdrawn
- 2001-06-19 JP JP2002504289A patent/JP5051959B2/ja not_active Expired - Fee Related
- 2001-06-19 AU AU7038101A patent/AU7038101A/xx not_active Withdrawn
- 2001-06-19 TR TR2007/04553T patent/TR200704553T2/xx unknown
- 2001-06-19 AU AU2001270381A patent/AU2001270381B2/en not_active Ceased
- 2001-06-19 EA EA200201280A patent/EA006232B1/ru not_active IP Right Cessation
- 2001-06-19 PL PL360413A patent/PL214229B1/pl unknown
- 2001-06-19 CZ CZ2003154A patent/CZ2003154A3/cs unknown
- 2001-06-20 AR ARP010102945A patent/AR033980A1/es not_active Application Discontinuation
- 2001-06-20 UY UY26783A patent/UY26783A1/es not_active Application Discontinuation
-
2002
- 2002-12-19 NO NO20026121A patent/NO331103B1/no not_active IP Right Cessation
- 2002-12-19 IL IL153558A patent/IL153558A/en not_active IP Right Cessation
-
2012
- 2012-05-23 JP JP2012117846A patent/JP5889103B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004501618A5 (enExample) | ||
| Watson et al. | Pneumococcal virulence factors and host immune responses to them | |
| JP2002542827A5 (enExample) | ||
| JP2003500040A5 (enExample) | ||
| CA2356836A1 (en) | Novel streptococcus antigens | |
| JP2003527079A5 (enExample) | ||
| EP2287188A1 (en) | Small Streptococcus pyogenes antigens and their use | |
| JP2002507396A5 (enExample) | ||
| JP2004513622A5 (enExample) | ||
| CA2395499A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
| EP1731166A3 (en) | Streptococcus pneumoniae proteins and vaccines | |
| CA2385325A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
| JP7146926B2 (ja) | Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン | |
| JP2006506989A5 (enExample) | ||
| WO2003065973A8 (en) | Multivalent streptococcal vaccine compositions and methods for use | |
| WO2001081380A3 (en) | Immunogenic pneumococcal protein and vaccine compositions thereof | |
| JP2025174963A (ja) | ヘモフィルス・パラスイスに対する新規ワクチン | |
| JP2002512800A5 (enExample) | ||
| JP2003530088A5 (enExample) | ||
| CA2413576A1 (en) | Streptococcus pyogenes antigens | |
| CN113633764B (zh) | 一种含佐剂的新冠dna疫苗 | |
| JPS63501683A (ja) | ボルデテラ・ペルトゥシス（□ＤＢｏｒｄｅｔｅｌｌａ ｐｅｒｔｕｓｓｉｓ）に対してワクチン作用を有する精製された抗原、この抗原を作成するための手段、特に組換えＤＮＡ及びこの抗原を含有するワクチン組成物 | |
| JP2016517402A (ja) | 自己組織化合成タンパク質（Ｓｅｌｆ−ＡｓｓｅｍｂｌｉｎｇＳｙｎｔｈｅｔｉｃＰｒｏｔｅｉｎｓ） | |
| JP2005512518A5 (enExample) | ||
| JP2002510493A (ja) | クラミジア感染症に対するｄｎａ免疫化 |